19.04.2018 • NewsDSM DyneemaElaine Burridge

DSM Dyneema Ends Patent Dispute with FMS

DSM Dyneema Ends Patent Dispute with FMS
DSM Dyneema Ends Patent Dispute with FMS

DSM Dyneema has concluded a dispute with Israeli firm FMS Enterprises Migun (FMS) relating to the infringement and validity of the Dutch company’s patents for ultra-high molecular weight polyethylene (UHMWPE).

Details of the agreement were not disclosed

This is the final step in a series of disputes between the two, including earlier unsuccessful attempts by FMS to challenge the validity of DSM Dyneema’s patent on an improved UHMWPE.

The latest action by DSM Dyneema against FMS was filed in November 2017 and was concluded in March this year.

“We are very pleased with this outcome, which again confirms the quality of our patents,” said Olivier Janin, vice president, marketing and sales at DSM Dyneema, adding that the company has consistently and vigorously defended its intellectual property on many occasions and will continue to do so.

DSM Dyneema has also ended another dispute with FMS relating to a patent concerning improved unidirectional sheets and pressed protective life saving articles made of such sheets, including inserts, helmets and vehicle panels. FMS had opposed DSM Dyneema’s patent, which was eventually granted on Mar. 22, 2018.

 

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.